XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 45.05

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.58M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-16 )

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.24% 76% C+ 55% F
Dividend Return 1.26% 94% A 24% F
Total Return 9.50% 81% B- 49% F
Trailing 12 Months  
Capital Gain 22.99% 81% B- 67% D+
Dividend Return 1.91% 100% F 27% F
Total Return 24.89% 86% B+ 65% D
Trailing 5 Years  
Capital Gain 16.56% 33% F 56% F
Dividend Return 6.43% 67% D+ 17% F
Total Return 22.99% 38% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain -1.50% 14% F 26% F
Dividend Return -0.81% 14% F 18% F
Total Return 0.69% 68% D+ 18% F
Risk Return Profile  
Volatility (Standard Deviation) 15.94% 67% D+ 65% D
Risk Adjusted Return -5.07% 10% F 19% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.